• Lipocalin-2 antibodies for methods of treatments. (US patent number: 8,481,032B2)

  • Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks. (US patent number: 8,030,097 B2)

  • Phosphoprotein target for insulin and insulin antagonists. (US patent number: US 6,884,575)

  • Adiponectin and uses thereof. (US patent Number: 7,365,170)

  • Lipocalin-2 as a diagnostic marker and therapeutic target. (US patent No: 7,645,616.)